Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
voxtalisib
- Development stage
- Phase 2
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Voxtalisib is an orally available, investigational small molecule that acts as a dual inhibitor of phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR). It inhibits all class I PI3K isoforms (α, β, γ, δ) and both mTORC1 and mTORC2 complexes. By targeting these kinases in the PI3K/mTOR signaling pathway, voxtalisib disrupts cellular processes critical for cancer cell growth and survival. The drug was developed for the treatment of various cancers including lymphoma, glioblastoma, breast cancer, melanoma, chronic lymphocytic leukemia (CLL), mantle-cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), ovarian cancer, solid tumors and others. Clinical trials showed some efficacy in follicular lymphoma but limited activity in other aggressive lymphomas or CLL/SLL. Voxtalisib development has been discontinued for all indications[1][2][6][9].
- Other names
- voxtalisib
02
Targets
mTOR (Mammalian target of rapamycin kinase)DNA-PK (DNA-dependent protein kinase)PIK3CD (Phosphatidylinositol 3-kinase delta)PIK3CA (Phosphoinositide 3-kinase alpha)PIK3CG (Phosphatidylinositol 4,5-bisphosphate 3-kinase gamma)PIK3CB (Phosphatidylinositol 3-kinase beta subunit)
Beyond the preview
Go deeper on voxtalisib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on voxtalisib.